The Long Case For Allergan plc (AGN)

Allergan plc (NYSE:AGN) is an interesting stock at present. Now trading with a market value of 56.47B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Allergan plc (NYSE:AGN) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For AGN, the company currently has 1.61 billion of cash on the books, which is offset by 3.8 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 118.99 billion in total assets, balanced by 47.82 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Allergan plc (AGN) saw 1.38 billion in free cash flow last quarter, representing a quarterly net change in cash of 725.8 million. Perhaps most importantly where cash movements are concerned, the company saw about 1.47 billion in net operating cash flow.

Allergan plc (NYSE:AGN) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 4.03 billion in total revenues. That represents a quarterly year/year change in revenues of 0.11 in sequential terms, the AGN saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Allergan plc (AGN) is intriguing when broken down to its core data. The cost of selling goods last quarter was 2.43 billion, yielding a gross basic income of 1.6 billion. For shareholders, given the total diluted outstanding shares of 333.5 million, this means overall earnings per share of -12.07. Note, this compares with a consensus analyst forecast of 4.73 in earnings per share for its next fiscal quarterly report.

Is Allergan plc (NYSE:AGN) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 16.12 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 10.81. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Allergan plc.

Previous ArticleNext Article

Related Post

OpGen, Inc. (OPGN) vs. VWR Corporation (VWR): Brea... OpGen, Inc. (NASDAQ:OPGN) and VWR Corporation (NASDAQ:VWR) are the two most active stocks in the Medical Laboratories & Research industry based on...
Checking Out the Fundamental Data for Gannett Co.,... Gannett Co., Inc. (NYSE:GCI) is an interesting stock at present. Now trading with a market value of 1.02B, the company has a mix of catalysts and obst...
Why Occidental Petroleum Corporation (OXY) Is Bein... It's worth it to have a look at Occidental Petroleum Corporation (NYSE:OXY) as there may be a chasm between the bulls and the bears as far as recent t...
Flex Ltd. (FLEX) Forming A Pattern Of Major Moveme... Flex Ltd. (NASDAQ:FLEX) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 7.58B...
The Fundamental Facts on Cognizant Technology Solu... Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has recently been identified as an interesting stock but more in-depth monitoring is needed f...